Form 4: NeuroSense CTO granted 200,000 restricted shares

CTO Niva Russek-Blum received 200,000 restricted ordinary shares at $0, vesting quarterly over two years, bringing direct holdings to 467,953.

Summary

• Niva Russek-Blum (Chief Technology Officer) acquired 200,000 restricted ordinary shares on 03/26/2026.
• Transaction code A (grant/award) at a price of $0 under the 2018 Share Incentive Plan.
• Post-transaction direct beneficial ownership totals 467,953 ordinary shares.
• Restricted shares vest in equal quarterly installments over two years, starting 03/26/2026, contingent on continued service.
• To qualify for Israeli Section 102 tax benefits, the securities are registered in the name of a trustee.
• Report signed on 03/30/2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as modestly positive for alignment and retention of a key executive, with limited standalone implications for financial performance.

Positives

• Equity award aligns the CTO’s incentives with shareholders through a two-year vesting schedule.
• Non-cash compensation ($0 grant price) conserves company cash resources.
• Clear vesting cadence (equal quarterly installments) supports retention and visibility of potential share issuance.

Negatives

• Grant increases potential share count, contributing to shareholder dilution.
• Two-year vesting is shorter than common three-to-four-year U.S. norms, potentially accelerating dilution versus longer schedules.
• No performance-based vesting criteria disclosed.

Risks

• Unvested restricted shares are subject to forfeiture if continued service conditions are not met.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider equity awards are common in biotech to retain key technical leaders and align incentives during long R&D cycles; quarterly vesting over two years is somewhat faster than typical U.S. biotech practice, but is not unusual for earlier-stage or smaller-cap companies.

Comparison to Industry Standards

• Vesting tenor: A two-year vesting period (quarterly) is shorter than the three-to-four-year vesting commonly seen among U.S. biotech executives (e.g., peers like Atea Pharmaceuticals, Iovance, or small-cap CNS-focused biotechs), implying faster potential dilution but quicker alignment for retention.
• Instrument type: Restricted shares at $0 grant price are standard for RS/RSU awards across biotech, in contrast to options which carry an exercise price; many small-cap peers similarly use RSUs/RS to conserve cash while retaining talent.
• Governance/tax structure: Use of an Israeli Section 102 trustee is typical for Israel-domiciled issuers and does not deviate from local market practice among Israeli life sciences companies.

Related Party Transactions

• Grant of 200,000 restricted ordinary shares at $0 to CTO Niva Russek-Blum under the 2018 Share Incentive Plan, held via trustee pursuant to Israeli Section 102.

Stakeholder Impact

• Shareholders: Slight dilution from the 200,000-share grant as vesting occurs.
• Employees/Executive: Strengthened retention and incentive alignment for the CTO through equity vesting.
• Regulatory/Tax: Trustee-held shares under Section 102 align with Israeli tax provisions, mainly affecting insider holding mechanics.

Next Steps

• Restricted shares vest in equal quarterly installments over two years beginning 03/26/2026, subject to continued service.

Key Dates

Keywords

NeuroSense Therapeutics, NRSN, Form 4, insider ownership, restricted stock, CTO, Section 102 Israeli Tax Ordinance, 2018 Share Incentive Plan, vesting schedule, biotechnology